Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors

Published:2019-10 Issue:10 Volume:27 Page:1825-1835
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Hombach Andreas A.,Rappl Gunter,Abken Hinrich

Funder

German Federal Ministry of Education and Research

Else Kröner-Fresenius-Stiftung

Deutsche Krebshilfe

Fortune Program of the Medical Faculty of the University of Cologne

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference46 articles.

1. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia;Porter;Sci. Transl. Med.,2015

2. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N. Engl. J. Med.,2014

3. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy;Bhoj;Blood,2016

4. T cell anergy;Schwartz;Annu. Rev. Immunol.,2003

5. CD30: expression and function in health and disease;Horie;Semin. Immunol.,1998

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release;Cancers;2024-08-01

3. The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer;Discover Oncology;2024-06-25

4. Magnetic CAR T cell purification using an anti-G4S linker antibody;Journal of Immunological Methods;2024-05

5. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors;Cancer Cell International;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3